Georgia Straight's digital sister publication, CannCentral, shines a light on burgeoning psychedelic sector

    1 of 1 2 of 1

      Cannabis aficionados frequently visit the CannCentral.com site to learn the latest info about the weed lifestyle. That's because of its ongoing coverage of cannabis news developments, strains, and dispensaries.

      This morning, the digital publication's owner, Media Central Corporation, announced that CannCentral is now sharply increasing coverage of the psychedelic sector.

      This new section will focus on therapeutic and medical applications of psychedelics, just as researchers are probing the impact that psilocybin might have on clinical depression.

      Media Central also owns the Georgia Straight in Vancouver and NOW magazine in Toronto.

      “The world of psychedelics is a natural extension of the content we produce at CannCentral,” Media Central CEO Brian Kalish said in a company news release. “Our 6.5 million audience of engaged influential readers have their fingers on the pulse of emerging trends and are eager to consume up-to-date information from our award-winning editorial teams.

      "Early signs point to the huge impact that psychedelics will have on society from a cultural, medical and business perspective," Kalish continued. "This focus on psychedelics is a natural progression of our ongoing strategy to leverage our considerable audience and capitalize on the latest in material trends as we move to further monetize our titles.”

      The Straight's Carlito Pablo wrote a story for CannCentral this week about a petition to decriminalize magic mushrooms and psychedelic plants in Canada. Many believe decriminalization is essential to bring new therapies to patients.

      If the petition attracts at least 500 signatures, Nanaimo-Ladysmith Green MP Paul Manly will present it on the floor of the House of Commons.

      A second new article on CannCentral, "Psychedelics as medicine poised to explode onto world markets", explains why 2020 promises to be a big year for the sector. It explores the latest clinical research and points out how Vancouver is seen as an epicentre in this area.

      Comments